Head and neck squamous cell cancer (stages III and IV) induction chemotherapy assessment: Value of FDG volumetric imaging parameters
暂无分享,去创建一个
Timothy Cooley | Gustavo Mercier | M. Truong | R. Subramaniam | G. Mercier | Minh-Tam Truong | Rathan M Subramaniam | Jielin Yu | T. Cooley | Jielin Yu
[1] Kristin D. Brockway,et al. What is the best way to contour lung tumors on PET scans? Multiobserver validation of a gradient-based method using a NSCLC digital PET phantom. , 2012, International journal of radiation oncology, biology, physics.
[2] M. Kikuchi,et al. Sequential FDG-PET/CT after Neoadjuvant Chemotherapy is a Predictor of Histopathologic Response in Patients with Head and Neck Squamous Cell Carcinoma , 2011, Molecular Imaging and Biology.
[3] B. C. Penney,et al. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer , 2011, European Journal of Nuclear Medicine and Molecular Imaging.
[4] Chun-Ta Liao,et al. Total lesion glycolysis: a possible new prognostic parameter in oral cavity squamous cell carcinoma. , 2013, Oral oncology.
[5] Jeanne Kowalski,et al. Assessment of Interobserver Reproducibility in Quantitative 18F-FDG PET and CT Measurements of Tumor Response to Therapy , 2009, Journal of Nuclear Medicine.
[6] Florent Tixier,et al. Prognostic value of 18F-FDG PET image-based parameters in oesophageal cancer and impact of tumour delineation methodology , 2011, European Journal of Nuclear Medicine and Molecular Imaging.
[7] A. Ozonoff,et al. FDG PET/CT interobserver agreement in head and neck cancer: FDG and CT measurements of the primary tumor site , 2012, Nuclear medicine communications.
[8] I. Kayani,et al. The potential advantages of (18)FDG PET/CT-based target volume delineation in radiotherapy planning of head and neck cancer. , 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[9] K. Frey,et al. Advanced squamous cell carcinoma of the oropharynx: Efficacy of positron emission tomography and computed tomography for determining primary tumor response during induction chemotherapy , 2009, Head & neck.
[10] J. Bourhis,et al. [Locally advanced head and neck cancers: recommendations of an expert panel and perspectives for the use of TPF regimen (docetaxel, cisplatin and fluoro-uracil) as induction therapy]. , 2009, Bulletin du cancer.
[11] M. Truong,et al. Fluorodeoxyglucose–Positron-Emission Tomography Imaging of Head and Neck Squamous Cell Cancer , 2010, American Journal of Neuroradiology.
[12] Su Jin Lee,et al. Prognostic Value of Metabolic Tumor Volume Measured by 18F-Fluorodeoxyglucose Positron Emission Tomography in Patients with Esophageal Carcinoma , 2009, Annals of Surgical Oncology.
[13] I. Buvat,et al. Comparative Assessment of Methods for Estimating Tumor Volume and Standardized Uptake Value in 18F-FDG PET , 2010, Journal of Nuclear Medicine.
[14] Rathan M. Subramaniam,et al. 18F-FDG Metabolic Tumor Volume and Total Glycolytic Activity of Oral Cavity and Oropharyngeal Squamous Cell Cancer: Adding Value to Clinical Staging , 2012, The Journal of Nuclear Medicine.
[15] R. Boellaard,et al. Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[16] M. Borri,et al. Changes in functional imaging parameters following induction chemotherapy have important implications for individualised patient-based treatment regimens for advanced head and neck cancer. , 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[17] R. Subramaniam,et al. Intra-reader reliability of FDG PET volumetric tumor parameters: effects of primary tumor size and segmentation methods , 2012, Annals of Nuclear Medicine.
[18] M. M. Qureshi,et al. A Prognostic Volumetric Threshold of Gross Tumor Volume in Head and Neck Cancer Patients Treated With Radiotherapy , 2014, American journal of clinical oncology.
[19] Baosheng Li,et al. Standard uptake value and metabolic tumor volume of 18F-FDG PET/CT predict short-term outcome early in the course of chemoradiotherapy in advanced non-small cell lung cancer , 2011, European Journal of Nuclear Medicine and Molecular Imaging.
[20] G. Calais,et al. Induction chemotherapy in head and neck cancer: a new paradigm , 2011, Anti-cancer drugs.
[21] B. C. Penney,et al. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer. , 2013, Academic radiology.
[22] D. Appelbaum,et al. Interobserver variability among measurements of the maximum and mean standardized uptake values on 18F-FDG PET/CT and measurements of tumor size on diagnostic CT in patients with pulmonary tumors , 2010, Acta radiologica.
[23] A. Ozonoff,et al. Use of 18F-FDG PET/CT as a predictive biomarker of outcome in patients with head-and-neck non-squamous cell carcinoma. , 2011, AJR. American journal of roentgenology.
[24] A. Clayton,et al. Hibernoma: 18F FDG PET/CT imaging. , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[25] Barry A Siegel,et al. Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: initial results from the National Oncologic PET Registry. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] J. Jett,et al. 18F‐fluoro‐2‐deoxy‐D‐glucose positron emission tomography and positron emission tomography/computed tomography imaging of malignant pleural mesothelioma * , 2009, Journal of medical imaging and radiation oncology.
[27] Quynh-Thu Le,et al. Validation that metabolic tumor volume predicts outcome in head-and-neck cancer. , 2012, International journal of radiation oncology, biology, physics.
[28] B. O'neill,et al. Contribution of F-18 FDG PET-CT in the Detection of Systemic Spread of Primary Central Nervous System Lymphoma , 2007, Clinical nuclear medicine.